Aβ38 and Aβ43 do not differentiate between Alzheimer's disease and cerebral amyloid angiopathy-Reference-Cited by-同舟云学术

Aβ38 and Aβ43 do not differentiate between Alzheimer's disease and cerebral amyloid angiopathy

Published:2024-01-07 Issue:3 Volume:11 Page:806-811
ISSN:2328-9503
Container-title:Annals of Clinical and Translational Neurology
language:en
Short-container-title:Ann Clin Transl Neurol

Author:

Dargvainiene Justina¹^ORCID,Jensen‐Kondering Ulf²³^ORCID,Bender Benjamin⁴,Berg Daniela⁵⁶,Brüggemann Norbert⁷,Flüh Charlotte⁸,Markewitz Robert¹,Neumann Alexander²,Röben Benjamin⁶⁹^ORCID,Röcken Christoph⁹,Royl Georg⁷,Schulte Claudia⁶¹⁰,Wandinger Klaus‐Peter¹,Weiler Caroline⁵,Margraf Nils G.⁵^ORCID,Kuhlenbäumer Gregor⁵^ORCID

Affiliation:

1. Institute of Clinical Chemistry University Medical Center Schleswig‐Holstein, Campus Kiel Kiel Germany

2. Department of Neuroradiology University Medical Center Schleswig‐Holstein, Campus Lübeck Lübeck Germany

3. Department of Radiology and Neuroradiology University Medical Center Schleswig‐Holstein, Campus Kiel, Kiel University (CAU) Kiel Germany

4. Department of Radiology, Diagnostical and Interventional Neuroradiology University Hospital of Tübingen Tübingen Germany

5. Department of Neurology University Medical Center Schleswig‐Holstein, Campus Kiel, Kiel University (CAU) Kiel Germany

6. Department of Neurodegeneration, Hertie Institute for Clinical Brain Research University of Tübingen Tübingen Germany

7. Department of Neurology University Medical Center Schleswig‐Holstein, Campus Lübeck Lübeck Germany

8. Department of Neurosurgery University Medical Center Schleswig‐Holstein, Campus Kiel, Kiel University (CAU) Kiel Germany

9. Department of Pathology University Medical Center Schleswig‐Holstein, Campus Kiel, Kiel University (CAU) Kiel Germany

10. German Center for Neurodegenerative Diseases University of Tübingen Tübingen Germany

Abstract

AbstractDifferential diagnosis between Alzheimer's disease (AD) and cerebral amyloid angiopathy (CAA) using cerebrospinal fluid (CSF) biomarkers is challenging. A recent study suggested that the addition of Aβ38 and Aβ43 to a standard AD biomarker panel (Aβ40, Aβ42, t‐tau, p‐tau) to improve the differential diagnosis. We tested this hypothesis in an independent German cohort of CAA and AD patients and controls using the same analytical techniques. We found excellent discrimination between AD and controls and between CAA and controls, but not between AD and CAA. Adding Aβ38 and Aβ43 to the panel did not improve the discrimination between AD and CAA.

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/acn3.51987

Reference16 articles.

1. Prevalence of superficial siderosis in patients with cerebral amyloid angiopathy

2. Prevalence of cerebral amyloid angiopathy: A systematic review and meta‐analysis

3. Lecanemab: appropriate use recommendations;Cummings J;J Prev Alzheimers Dis,2023

4. Cerebrospinal Fluid Biomarkers in Cerebral Amyloid Angiopathy: New Data and Quantitative Meta-Analysis

5. Reply to "Decreased Cerebrospinal Fluid Amyloid Beta 38, 40, 42, and 43 Levels in Sporadic and Hereditary Cerebral Amyloid Angiopathy"

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cerebrospinal fluid in the differential diagnosis of Alzheimer’s disease: an update of the literature;Expert Review of Neurotherapeutics;2024-09-04